OC-0270: QoL and toxicity of HDR prostate brachytherapy as monotherapy 19Gy single fraction:phase II trial
Alfonso Gómez‐Iturriaga(BioCruces Health research Institute), P. Bilbao(Universidad Nacional del Sur), Salvador Pedraza(Hospital Clínic de Barcelona), J. Garcia Escovedo, P. Mı́nguez, José María Lamo-Espinosa, Jon Cacicedo(BioCruces Health research Institute), Andrea Bueso, L. Fernández, F. Casquero
Cited by 0
Related Papers
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
|New England Journal of Medicine|2018|1.3k
Perfusion-CT Assessment of Infarct Core and Penumbra
|Stroke|2006|771
Comparative Overview of Brain Perfusion Imaging Techniques
|Stroke|2005|586